Elevance Health cuts chemo hospital admissions by 66% with care model
Elevance Health’s Cancer Care Engagement program reduced chemotherapy-related hospital admissions by 66% and 30-day readmissions by 25%. With an 84% patient engagement rate, the model uses predictive analytics and oncology navigators to support 1.8 million annual U.S. cancer diagnoses. Provider partnerships further enhance treatment consistency and reduce waste.
*this image is generated using AI for illustrative purposes only.
Elevance Health has strengthened its connected cancer care model, reporting a 66% reduction in hospital admissions for chemotherapy-related side effects among participants. The company’s Cancer Care Engagement (CCE) program combines advanced analytics with dedicated clinical support to identify at-risk patients early, aiming to simplify navigation for the 1.8 million people diagnosed with cancer annually in the U.S. This approach addresses both medical and logistical burdens, seeking to improve outcomes for Elevance Health’s portfolio of approximately 105 million consumers.
The initiative relies on predictive analytics to flag patients at higher risk for complications, connecting them with certified oncology navigators who serve as consistent points of contact. These navigators coordinate care, answer questions, and link patients to supportive services such as behavioral health, transportation, and pharmacy support. Among patients reached, the program has achieved an 84% engagement rate.
Operational Impact
The integration of digital care management and personalized outreach has yielded measurable reductions in avoidable healthcare utilization. By addressing clinical and day-to-day needs through tailored care plans and 24/7 support, the program helps patients stay on track with treatment.
| Metric | Improvement |
|---|---|
| Hospital admissions (chemo side effects) | 66% reduction |
| 30-day readmissions | 25% reduction |
| Avoidable inpatient admissions (Medicare Advantage) | 7% reduction |
| Avoidable inpatient admissions (Commercially insured) | 15% reduction |
| Patient engagement rate | 84% |
David Debono, MD, Oncology Medical Director at Carelon Health, Elevance Health’s care delivery and services organization, stated that a proactive, connected approach guides patients through their journey and ensures they receive appropriate care at the right time.
Provider Enablement
Beyond direct patient support, Elevance Health partners with oncology providers through Oncology Provider Enablement Clinicians (OPECs). These clinicians use data-driven dashboards to track key metrics and pathway adherence alongside oncologists. This collaboration aims to improve treatment consistency, reduce drug waste, and lower emergency room visits.
What the Numbers Show
The disparity in avoidable admission reductions between Medicare Advantage members (7%) and commercially insured members (15%) suggests varying baseline complexities or utilization patterns across payer types. However, the uniform high engagement rate of 84% indicates that the navigator-led model effectively reaches diverse patient populations regardless of insurance structure. The significant 66% drop in chemotherapy-related admissions highlights the efficacy of proactive symptom management over reactive hospital care.
How might Elevance Health's success with oncology navigators influence the broader adoption of similar care coordination models for other chronic conditions?
What are the long-term financial implications for Elevance Health if the 66% reduction in chemo-related admissions scales across its entire 105 million-member portfolio?
Will the disparity in admission reductions between Medicare Advantage and commercially insured members persist as the program matures, or will targeted interventions narrow this gap?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
